Skip to main content
. 2024 Mar 21;15(2):223–238. doi: 10.14740/wjon1790

Table 2. irAEs and Response Rate According to Histology.

Histology Toxicity Re-evaluation
CR PR SE PD NE
Adenocarcinoma Yes (77) 13 31 21 8 4
No (39) 0 3 6 21 9
Squamous Yes (27) 2 12 9 4 0
No (25) 0 4 3 12 6

CR: complete response; irAEs: immune-related adverse events; NE: not evaluated; PD: progressive disease; PR: partial response; SD: stable disease.